KR20160009677A - 암 치료를 위한 ro5503781, 카페시타빈과 옥살리플라틴의 조합 - Google Patents

암 치료를 위한 ro5503781, 카페시타빈과 옥살리플라틴의 조합 Download PDF

Info

Publication number
KR20160009677A
KR20160009677A KR1020157035737A KR20157035737A KR20160009677A KR 20160009677 A KR20160009677 A KR 20160009677A KR 1020157035737 A KR1020157035737 A KR 1020157035737A KR 20157035737 A KR20157035737 A KR 20157035737A KR 20160009677 A KR20160009677 A KR 20160009677A
Authority
KR
South Korea
Prior art keywords
day
phenyl
component
fluoro
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020157035737A
Other languages
English (en)
Korean (ko)
Inventor
브라이언 히긴스
그웬 니콜스
캐쓰린 이 팩맨
Original Assignee
에프. 호프만-라 로슈 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에프. 호프만-라 로슈 아게 filed Critical 에프. 호프만-라 로슈 아게
Publication of KR20160009677A publication Critical patent/KR20160009677A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Dermatology (AREA)
KR1020157035737A 2013-06-19 2014-06-16 암 치료를 위한 ro5503781, 카페시타빈과 옥살리플라틴의 조합 Ceased KR20160009677A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361836899P 2013-06-19 2013-06-19
US61/836,899 2013-06-19
PCT/EP2014/062496 WO2014202497A1 (en) 2013-06-19 2014-06-16 Combination of ro5503781, capecitabine and oxaliplantin for cancer therapy

Publications (1)

Publication Number Publication Date
KR20160009677A true KR20160009677A (ko) 2016-01-26

Family

ID=50976625

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157035737A Ceased KR20160009677A (ko) 2013-06-19 2014-06-16 암 치료를 위한 ro5503781, 카페시타빈과 옥살리플라틴의 조합

Country Status (12)

Country Link
US (1) US20160129034A1 (enExample)
EP (1) EP3010508B1 (enExample)
JP (1) JP6549107B2 (enExample)
KR (1) KR20160009677A (enExample)
CN (1) CN105263499B (enExample)
BR (1) BR112015030734A2 (enExample)
CA (1) CA2912743A1 (enExample)
ES (1) ES2747073T3 (enExample)
MX (1) MX2015017124A (enExample)
PL (1) PL3010508T3 (enExample)
RU (1) RU2015152175A (enExample)
WO (1) WO2014202497A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021033144A1 (en) * 2019-08-20 2021-02-25 Intas Pharmaceuticals Ltd. Oral suspension of capecitabine
CN113698435B (zh) * 2021-08-25 2023-09-29 中国人民解放军空军军医大学 一类含有p53-MDM2抑制剂的四价铂配合物及其制备方法与应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007107543A1 (en) * 2006-03-22 2007-09-27 Janssen Pharmaceutica N.V. Inhibitors of the interaction between mdm2 and p53
EP3175853B1 (en) * 2008-08-04 2023-11-01 Wyeth LLC Antineoplastic combinations of neratinib and capecitabine
US8354444B2 (en) * 2008-09-18 2013-01-15 Hoffmann-La Roche Inc. Substituted pyrrolidine-2-carboxamides

Also Published As

Publication number Publication date
MX2015017124A (es) 2016-03-07
EP3010508A1 (en) 2016-04-27
ES2747073T3 (es) 2020-03-10
BR112015030734A2 (pt) 2017-07-25
CA2912743A1 (en) 2014-12-24
RU2015152175A (ru) 2017-07-24
EP3010508B1 (en) 2019-07-24
JP2016521760A (ja) 2016-07-25
HK1213475A1 (zh) 2016-07-08
US20160129034A1 (en) 2016-05-12
JP6549107B2 (ja) 2019-07-24
CN105263499B (zh) 2019-11-15
CN105263499A (zh) 2016-01-20
PL3010508T3 (pl) 2019-12-31
RU2015152175A3 (enExample) 2018-04-02
WO2014202497A1 (en) 2014-12-24

Similar Documents

Publication Publication Date Title
KR101673731B1 (ko) 벰루페닙 및 mdm2 억제제의, 증식성 질환 치료용 복합 요법
ES2828177T3 (es) Procedimiento para el tratamiento de tumor, composición farmacéutica y botiquín
JP5046922B2 (ja) 少なくとも一つのピロロベンゾジアゼピン誘導体とフルダラビンとを含有する治療用組成物
EP2817011B1 (en) Treatment of cancer
JP5579715B2 (ja) ｃｄｋ阻害剤および抗悪性腫瘍剤を含む治療用組合せ
JP2012515184A (ja) 大腸がんの治療方法
CN102006875A (zh) 吡铂和贝伐单抗治疗结直肠癌的用途
EP3010508B1 (en) Combination of ro5503781, capecitabine and oxaliplatin for cancer therapy
EP2268287B1 (en) Dosage regimens of an antitumor agent comprising deoxycytidine derivative
EP1872798B1 (en) Intestinal absorptive anti-tumor agent
EP2262493B1 (en) Methods of treatment employing prolonged continuous infusion of belinostat
EP3010513B1 (en) Combination of ro5503781 and capecitabine for cancer therapy
HK1213475B (en) Combination of ro5503781, capecitabine and oxaliplantin for cancer therapy
US8168662B1 (en) Use of picoplatin to treat colorectal cancer
HK1204956B (en) Treatment of cancer

Legal Events

Date Code Title Description
A201 Request for examination
PA0105 International application

Patent event date: 20151217

Patent event code: PA01051R01D

Comment text: International Patent Application

PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20151217

Comment text: Request for Examination of Application

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20170203

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20170822

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20170203

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I